Antihypertension effect of astragalosideIV during cerebral ischemia reperfusion in rats.

Abstract

Stroke is one of the leading causes of death from diseases. When the blood supply to the brain tissue is interrupted, neuronal core death occurs due to the lack of glucose and oxygen in min. Blood pressure lowering after ischemic stroke was proven to be an effective strategy to achieve neurovascular protection and reduce the risk of recurrent stroke. AstragalosideIV is a pure small molecular compound isolated from Radix Astragali, and it is well documented that astragalosideIV has neuroprotective effect on cerebral ischemia reperfusion (CIR) injury through many mechanisms, including antioxidant, anti‑inflammatory and anti‑apoptotic. The present study adopted mean arterial pressure (MAP) monitoring, neurological scoring, 2,3,5‑triphenyltetrazolium chloride staining, enzyme‑linked immuno‑sorbent assay, western blotting and other experimental methods to investigate the effect of astragalosideIV on systemic blood pressure during CIR in a middle cerebral artery occlusion animal model. It was demonstrated that astragalosideIV pretreatment significantly alleviated CIR injury as previously reported. In addition, the elevation of MAP during CIR was significantly inhibited by astragalosideIV administration. Moreover, it was revealed that the expression of Na+‑K+‑2Cl‑ cotransporter isoform1 in the hypothalamus was inhibited and the subsequent synthesis of vasopressin was reduced by astragalosideIV pretreatment in the CIR animal model. In conclusion, astragalosideIV may alleviate CIR injury partially by lowering systemic blood pressure.